1. Volume 136, Issue 2, Pages 496-504.e3 (February 2009)
Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses 
Chun–Jen Liu, Wan–Long Chuang, Chuan–Mo Lee, Ming–Lung Yu, Sheng–Nan Lu, Shun–Sheng Wu, Li–Ying Liao, Chi–Ling Chen, Hsing–Tao Kuo, You–Chen Chao, Shui–Yi Tung, Sien–Sing Yang, Jia–Horng Kao, Chen–Hua Liu, Wei–Wen Su, Chih–Lin Lin, Yung– Ming Jeng, Pei–Jer Chen, Ding–Shinn Chen 
Gastroenterology 
Volume 136, Issue 2, Pages e3 (February 2009)
DOI: /j.gastro
Copyright © 2009 AGA Institute Terms and Conditions

2. Figure 1
Study design of a multicenter clinical trial. The study group comprised 161 HBsAg-positive patients with chronic hepatitis C, and 160 HBsAg-negative patients with chronic hepatitis C served as controls.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2009 AGA Institute Terms and Conditions

3. Figure 2
Hepatitis C viral responses to the combination therapy of peginterferon alfa-2a and ribavirin. ITT (intention-to-treat), analysis of patients receiving at least one dose of study treatment including withdrawals; withdrawn cases without HCV-RNA testing at 24 weeks posttreatment are counted as treatment failure; PP (per-protocol), analysis of patients completing at least 12 weeks of treatment; B + C, HBsAg-positive patients with chronic hepatitis C; C, HBsAg-negative patients with chronic hepatitis C; VR, HCV-RNA clearance at the end of treatment; SVR, HCV-RNA clearance at 24 weeks posttreatment.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2009 AGA Institute Terms and Conditions

4. Figure 3
Rates of serum ALT normalization in comparison with HCV SVR at the end of the follow-up period. The majority of patients with SVR had normal ALT levels at the end of the follow-up period. However, 29 (23.6%) of 123 dually infected patients with SVR still had increased ALT levels at the end of the follow-up period.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2009 AGA Institute Terms and Conditions

5. Supplementary Figure 1
Profiles of serum ALT level in the 28 dually infected patients who had undetectable serum HBV DNA pre-treatment but developed HBV DNA reappearance post-treatment. Each line indicates the dynamics of serum ALT level in each case.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2009 AGA Institute Terms and Conditions